JP6989505B2 - Ｍａｌｔ１阻害剤およびその使用 - Google Patents

Ｍａｌｔ１阻害剤およびその使用 Download PDF

Info

Publication number
JP6989505B2
JP6989505B2 JP2018529516A JP2018529516A JP6989505B2 JP 6989505 B2 JP6989505 B2 JP 6989505B2 JP 2018529516 A JP2018529516 A JP 2018529516A JP 2018529516 A JP2018529516 A JP 2018529516A JP 6989505 B2 JP6989505 B2 JP 6989505B2
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
certain embodiments
substituted
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018529516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531987A (ja
JP2018531987A5 (enExample
Inventor
スコット，デイヴィッド，エー．
ハッチャー，ジョン
チェンナマダヴーニ，スパンダン
ギャバス，ロレナ，フォンタン
カオ，キ
ドゥ，グァンヤン
メルニク，アリ，エム．
グレイ，ナサニエル，エス．
ウー，ハオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Dana Farber Cancer Institute Inc
Original Assignee
Boston Children's Hospital
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Children's Hospital, Dana Farber Cancer Institute Inc filed Critical Boston Children's Hospital
Publication of JP2018531987A publication Critical patent/JP2018531987A/ja
Publication of JP2018531987A5 publication Critical patent/JP2018531987A5/ja
Priority to JP2021135770A priority Critical patent/JP2021193093A/ja
Application granted granted Critical
Publication of JP6989505B2 publication Critical patent/JP6989505B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018529516A 2015-08-28 2016-08-26 Ｍａｌｔ１阻害剤およびその使用 Active JP6989505B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021135770A JP2021193093A (ja) 2015-08-28 2021-08-23 Ｍａｌｔ１阻害剤およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562211629P 2015-08-28 2015-08-28
US62/211,629 2015-08-28
US201562256672P 2015-11-17 2015-11-17
US62/256,672 2015-11-17
PCT/US2016/049038 WO2017040304A1 (en) 2015-08-28 2016-08-26 Malt1 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021135770A Division JP2021193093A (ja) 2015-08-28 2021-08-23 Ｍａｌｔ１阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2018531987A JP2018531987A (ja) 2018-11-01
JP2018531987A5 JP2018531987A5 (enExample) 2019-10-03
JP6989505B2 true JP6989505B2 (ja) 2022-01-05

Family

ID=58188144

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018529516A Active JP6989505B2 (ja) 2015-08-28 2016-08-26 Ｍａｌｔ１阻害剤およびその使用
JP2021135770A Pending JP2021193093A (ja) 2015-08-28 2021-08-23 Ｍａｌｔ１阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021135770A Pending JP2021193093A (ja) 2015-08-28 2021-08-23 Ｍａｌｔ１阻害剤およびその使用

Country Status (4)

Country Link
US (1) US10711036B2 (enExample)
EP (1) EP3341007B1 (enExample)
JP (2) JP6989505B2 (enExample)
WO (1) WO2017040304A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3736277A1 (en) 2016-07-29 2020-11-11 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018020474A1 (en) 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
EP3495348A4 (en) * 2016-07-29 2020-01-22 Toray Industries, Inc. GUANIDINE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
KR20200105678A (ko) * 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
AU2019289223B2 (en) * 2018-06-18 2023-09-21 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
EA202190055A1 (ru) * 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
EP3863625A4 (en) * 2018-10-09 2022-06-29 The Research Institute at Nationwide Children's Hospital Anticancer rocaglamide derivatives
CN111358959B (zh) * 2019-10-10 2021-03-26 鹿文葆 Roquin1蛋白及其编码基因在制备抑制肿瘤的药物中的应用
CN111686111B (zh) * 2020-06-09 2023-06-13 南方医科大学 Malt1蛋白酶抑制剂在制备非小细胞肺癌治疗药物中的应用
WO2022081967A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN113024565B (zh) * 2021-03-31 2022-09-13 上海启甄环境科技有限公司 一种放射性同位素碳-14标记依鲁替尼及其合成方法
WO2023149945A1 (en) * 2022-02-03 2023-08-10 Purdue Research Foundation Peptidomimetic inhibitors of protein n-terminal methyltransferase 1, composition, and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210272A (en) 1990-02-16 1993-05-11 Prototek, Inc. Process for forming a fluoromethyl ketone
CA2253835A1 (en) 1996-06-18 1997-12-24 Kent Alan Berryman Process for the preparation of chiral keto-heterocycles of basic amino acids
KR20020029419A (ko) 1999-07-07 2002-04-18 다비드 에 질레스 퀴나졸린 유도체
JP5479105B2 (ja) 2007-11-05 2014-04-23 国立大学法人佐賀大学 新規ユビキリン結合性小分子
US8993758B2 (en) 2010-11-22 2015-03-31 Board Of Regents Of The University Of Nebraska Substituted quinoxalines and uses thereof
EA201590916A1 (ru) 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6545197B2 (ja) 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用
US10689366B2 (en) 2016-11-01 2020-06-23 Cornell University Compounds for MALT1 degredation

Also Published As

Publication number Publication date
EP3341007A1 (en) 2018-07-04
US10711036B2 (en) 2020-07-14
EP3341007B1 (en) 2020-12-23
JP2021193093A (ja) 2021-12-23
US20180251489A1 (en) 2018-09-06
JP2018531987A (ja) 2018-11-01
WO2017040304A1 (en) 2017-03-09
US20190389904A2 (en) 2019-12-26
EP3341007A4 (en) 2019-05-01

Similar Documents

Publication Publication Date Title
JP2021193093A (ja) Ｍａｌｔ１阻害剤およびその使用
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP7472026B2 (ja) 選択的なタンパク質分解を誘導するための低分子およびその使用法
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
EP3876939A1 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP2021528470A (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
KR20160034379A (ko) 전사 인자의 억제제 및 그의 용도
JP7821573B2 (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
JP2019505548A (ja) Ｍｙｃモジュレーターとしてのｍａｘバインダーおよびこれらの使用
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
JP2022516745A (ja) Ｄｏｔ１ｌ分解剤およびその使用
AU2019318046A1 (en) Histone demethylase 5 inhibitors and uses thereof
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210823

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210831

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210930

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211202

R150 Certificate of patent or registration of utility model

Ref document number: 6989505

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250